Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

On Eve Of House Hearing, FDA Makes Its Case For LDT Framework

This article was originally published in The Gray Sheet

Executive Summary

The agency details 20 case studies to support its planned framework for regulating laboratory-developed tests in a report issued the day before a House subcommittee held a hearing on alternative legislative schemes.

You may also be interested in...



Diagnostics Reg Overhaul Floated In US House

Lawmakers are circulating draft legislation that would create a new regulatory category, distinct from medical devices, combining in vitro diagnostics and laboratory-developed tests. The representatives say they don't have specific timing in mind for moving the bill forward. But it is being circulated just as the FDA user-fee reauthorization process is getting off the ground, presenting a possible legislative vehicle.

What's Next For LDTs? FDA May Be Eyeing A New Game Plan

Following the agency's signal to stakeholders that it will not be finalizing a regulatory framework for laboratory-developed tests this year, industry experts suggest some other approaches FDA could take to address lab tests of all stripes.

In Case You Missed It: Top 10 "Gray Sheet" Stories In November

Our most popular stories last month included an exclusive item on FDA's next steps for its device Case-for-Quality program; a graphical analysis of the agency's MDUFA III performance, three years into the program; a guest column from a former CDRH Office of Compliance director; and more.

Related Content

Topics

UsernamePublicRestriction

Register

MT034395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel